CDKN2A and neoplasm: After multivariable adjustment for clinical and tumor features (see “Methods”), CDKN2A deletion remained predictive of survival after mono-IO treatment with an adjusted hazard ratio of 1.9 [1.3–2.7] and 1.1 [0.8–1.4] for mono-IO and chemo-IO cohorts respectively.